664 related articles for article (PubMed ID: 17419947)
1. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
Cao Y; Liu Q
Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
3. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
Grépin R; Pagès G
J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
5. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
6. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
7. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
9. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
10. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
Cézé N; Lecomte T; Watier H
Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685
[TBL] [Abstract][Full Text] [Related]
11. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
12. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
16. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
17. Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression.
Bzowska M; Mężyk-Kopeć R; Próchnicki T; Kulesza M; Klaus T; Bereta J
Acta Biochim Pol; 2013; 60(3):263-75. PubMed ID: 23819129
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
19. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
20. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
